

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8329)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Shenzhen Neptunus Interlong Bio-technique Company Limited (the “**Company**”) is pleased to announce that Mr. Jin Rui (“**Mr. Jin**”) has been appointed as a non-executive Director with effect from 13 May 2022.

The biographical details of Mr. Jin are set out below:

Mr. Jin Rui (金銳), aged 38, is currently the vice president of Shenzhen Neptunus Bio-engineering Company Limited* (“**Neptunus Bio-engineering**”, the controlling shareholder of the Company whose shares are listed on the Shenzhen Stock Exchange) and a director of Henan Neptunus Pharmaceutical Group Company Limited, Shandong Neptunus Pharmaceutical Group Company Limited, Guangdong Neptunus Pharmaceutical Group Company Limited, Hebei Neptunus Pharmaceutical Group Company Limited, Sulu Neptunus Pharmaceutical Group Company Limited, Anhui Neptunus Pharmaceutical Group Company Limited, Fuzhou Neptunus Fuyao Pharmaceutical Company Limited and Fuzhou Neptunus Jinxiang Chinese Pharmaceutical Company Limited. Mr. Jin previously served various roles in the management level in a number of companies including, as the assistant president of Holley Group Co., Ltd., the vice president of Holley Pharmaceutical Group Co., Ltd, the director of Zhejiang Wazam New Materials Co., Ltd., the director and the president of Zhejiang Huafang Asset Management Co., the chairman of Zhejiang Huafang Life Technology Co., Ltd., and the chairman of Tibet Tibetan Medicine (Group) Li Zhong Yuan Biotechnological Co., Ltd. Mr. Jin joined Neptunus Bio-engineering as the executive vice president in August 2021.

Mr. Jin obtained his bachelor’s degree in Nanjing University in 2007 and a master’s degree in Zhejiang University in 2013.

Mr. Jin has entered into a service contract with the Company for a term commencing on 13 May 2022 until the next annual general meeting of the Company and is eligible for re-election at the meeting and will also be subject to the retirement by rotation and re-election in accordance with the articles of association of the Company. His appointment may be terminated by either party giving not less than three months' written notice to the other. Under the terms of the service contract, Mr. Jin will be entitled to an annual remuneration of RMB100,000 (which is tax inclusive and to be paid on a monthly basis with the Company being responsible for withholding personal income tax), which is determined based on the prevailing market practice, his duties, responsibilities, contribution to the Company and the remuneration of other non-executive Directors, and shall be reviewed by the Remuneration Committee from time to time. Within the permitted scope regulated by relevant laws, regulations and policies of the People's Republic of China, any reasonable and necessary expenses (including but not limited to travel expenses) paid by Mr. Jin for the provision of director's service to the Company or due to the execution of work relevant to the Company's operation will be borne by the Company.

As at the date of this announcement, save as disclosed above, Mr. Jin (i) has not held any directorships during the last three years in other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iii) does not have any relationships with other Directors, senior management, or substantial or controlling shareholders of the Company.

Save as disclosed above, there is no other matter that needs to be brought to the attention of the Shareholders and there is no other information requiring to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited ("**GEM Listing Rules**") in connection with the appointment of Mr. Jin.

Following the appointment of Mr. Jin, the total number of the Directors will comply with the minimum requirement under the articles of association of the Company.

The Board would like to take this opportunity to express welcome for Mr. Jin's appointment.

By order of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

Shenzhen, the PRC, 13 May 2022

As at the date of this announcement, the executive Directors are Mr. Zhang Feng and Mr. Huang Jian Bo; the non-executive Directors are Mr. Zhang Yi Fei, Ms. Yu Lin, Mr. Shen Da Kai and Mr. Jin Rui; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material aspects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company’s website at www.interlong.com.

** For identification purpose only*